Genome-wide association studies promise to discover novel indicators of hypertension. Endothelin-related SNPs are currently in clinical trials

Abstract

Nevertheless, in the field of hypertension genomics, it is likely that new genetic markers will be identified, but until they are, the results are restricted. Following on from this, and by drawing from pharmacogenomic, pleiotropic, and functional studies, the follow-up and clinical translation of these genetic results seems to be very promising. These endothelin-related SNPs, which have gone on to the clinical trial stage, signify further success in the advancement of hypertension precision medicine that has already been discovered through genetic research. Although the use of polygenic risk scores may appear advantageous, further study is required to verify their effectiveness, and this issue must be examined further to determine the potential for these scores to lead to an increase in health inequity.